Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 7
Submit an article Journal homepage
207
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR

Ivar O. KommersDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia; ;VU University Medical Center, Amsterdam, The Netherlands;
,
Paul A. BartleyDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia;
,
Bradley BudgenDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia;
,
Sue LathamDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia;
,
Ashanka BeligaswatteDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia;
,
Shane G. SuppleInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia;
,
Alberto CatalanoInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia;
,
Harry J. IlandInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia; ;Sydney Medical School, University of Sydney, Sydney, Australia;
,
Alexander A. MorleyDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia;
&
David M. RossDepartment of Clinical and Molecular Medicine, Flinders University and Medical Centre, Adelaide, Australia; ;School of Medicine, University of Adelaide, Adelaide, AustraliaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7171-2935
ORCID Icon show all
Pages 1767-1769 | Received 08 Sep 2016, Accepted 12 Nov 2016, Published online: 30 Nov 2016

References

  • Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570–1580. quiz 1752.
  • Grimwade D, Jovanovic JV, Hills RK. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?. Best Pract Res Clin Haematol. 2014;27:53–61.
  • Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999;93:4131–4143.
  • Bartley PA, Ross DM, Latham S, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol. 2010;32:e222–e228.
  • Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719–1724.
  • Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97:227–234.
  • Bartley PA, Martin-Harris MH, Budgen BJ, et al. Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. Br J Haematol. 2010;149:231–236.
  • Brisco MJ, Latham S, Bartley PA, et al. Incorporation of measurement of DNA integrity into qPCR assays. Biotechniques. 2010;49:893–897.
  • Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198–205.
  • Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650–3658.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.